Vaccine Developer HilleVax Stock Nosedives On Monday - Here's Why

Loading... Monday, the company released topline data results from the NEST-IN1 Phase 2b randomized, double-blind, placebo-controlled trial of the efficacy, safety, and immunogenicity of HIL-214 in infants approximately five months of age at the time of initial vaccination. In the NEST-IN1 study, there were 51 primary endpoint events, with 25 in the vaccine arm (n=1,425) and 26 in the placebo arm (n=1,399), resulting in a vaccine efficacy of 5%. "We are disappointed that the NEST-IN1 study did not meet its p ...